Janux Therapeutics Inc (JANX)

$14.05 +0.17 (1.22%)
Market Cap 826.10M
Revenue (ttm) 10.00M
Net Income (ttm) -113.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,136.30%
Debt to Equity Ratio 0.00
Volume 1,395,900
Avg Vol 1,306,670
Day's Range N/A - N/A
Shares Out 60.83M
Stochastic %K 48%
Beta 2.88
Analysts Strong Sell
Price Target $48.81

Company Profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cance...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 751 4493
Address:
10955 Vista Sorrento Parkway, Suite 200, San Diego, United States
MarketWarfare
MarketWarfare Mar. 17 at 7:30 PM
$JANX broken, pathetic stock. Wasting all these green days so that when the market turns red, we'll get an easy 5% decline. CEO needs to go.
0 · Reply
Dieselprints
Dieselprints Mar. 16 at 5:06 PM
$JANX picked up 1k shares
0 · Reply
bizness1957
bizness1957 Mar. 16 at 1:55 PM
$JANX should break out today
0 · Reply
bc4
bc4 Mar. 13 at 4:12 PM
$JANX This seems to be algo trading on this stock. The patern and timing of short and cover always the same everyday.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 12 at 10:42 PM
$JANX RSI: 64.84, MACD: 0.0308 Vol: 0.37, MA20: 13.62, MA50: 13.71 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
nikserr
nikserr Mar. 12 at 5:45 PM
$JANX Started accumulating … Easy 20+
0 · Reply
MarketWarfare
MarketWarfare Mar. 12 at 1:57 PM
$JANX market down 600, janx down 50 cents. Market up 600, janx up 1 cent. Nothing changes until the pos CEO is removed. He's abysmal.
0 · Reply
aletz
aletz Mar. 12 at 1:47 PM
$JANX https://www.biostockinfo.com/t-cell-engagers-tce-the-race-to-reset-the-immune-system-and-the-biotechs-positioning-to-win/ This can help understand what TCE is about and how JANX-011 fits in the space
0 · Reply
Suhair1977
Suhair1977 Mar. 12 at 9:50 AM
$JANX Price targets $80 and $100. Let’s talk about $20 first
0 · Reply
MarketWarfare
MarketWarfare Mar. 10 at 4:12 PM
$JANX green market, dead stock. What else is new?
0 · Reply
Latest News on JANX
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Feb 26, 2026, 4:01 PM EST - 19 days ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Feb 17, 2026, 7:00 AM EST - 4 weeks ago

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Jan 26, 2026, 7:00 AM EST - 7 weeks ago

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Jan 22, 2026, 2:02 PM EST - 7 weeks ago

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

BMY

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

Jan 22, 2026, 7:38 AM EST - 7 weeks ago

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

BMY

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

Jan 22, 2026, 7:00 AM EST - 7 weeks ago

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Dec 23, 2025, 4:05 PM EST - 3 months ago

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Dec 2, 2025, 10:58 AM EST - 3 months ago

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Janux dives as gaps in prostate cancer study data worry investors

Dec 2, 2025, 10:50 AM EST - 3 months ago

Janux dives as gaps in prostate cancer study data worry investors

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Dec 2, 2025, 8:41 AM EST - 3 months ago

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

BWLP SIG

Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.

Dec 2, 2025, 8:30 AM EST - 3 months ago

Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

Dec 1, 2025, 11:13 PM EST - 3 months ago

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Dec 1, 2025, 4:05 PM EST - 3 months ago

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

Nov 24, 2025, 8:00 AM EST - 4 months ago

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:01 PM EST - 4 months ago

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 7, 2025, 4:01 PM EDT - 7 months ago

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

Aug 5, 2025, 4:05 PM EDT - 8 months ago

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

Jul 31, 2025, 12:01 AM EDT - 8 months ago

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Jul 24, 2025, 4:05 PM EDT - 8 months ago

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

Jul 17, 2025, 4:30 PM EDT - 8 months ago

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

May 15, 2025, 8:00 AM EDT - 10 months ago

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:01 PM EDT - 11 months ago

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

May 5, 2025, 8:30 AM EDT - 11 months ago

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Apr 5, 2025, 8:14 AM EDT - 1 year ago

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 27, 2025, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Jan 24, 2025, 4:01 PM EST - 1 year ago

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Jan 8, 2025, 9:00 AM EST - 1 year ago

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Best-Performing Stocks Of 2024

Jan 2, 2025, 11:46 PM EST - 1 year ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD LUNR MSTR

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Dec 6, 2024, 7:43 PM EST - 1 year ago

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Dec 4, 2024, 11:12 PM EST - 1 year ago

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics Announces Proposed Public Offering

Dec 3, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Announces Proposed Public Offering

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

Dec 3, 2024, 10:49 AM EST - 1 year ago

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

Dec 3, 2024, 10:39 AM EST - 1 year ago

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Dec 2, 2024, 4:30 PM EST - 1 year ago

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Nov 25, 2024, 9:00 AM EST - 1 year ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Nov 19, 2024, 1:23 AM EST - 1 year ago

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 6, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics Announces Updates to Board of Directors

Jul 22, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Announces Updates to Board of Directors

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

Jun 26, 2024, 8:32 AM EDT - 1 year ago

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 4:01 PM EDT - 2 years ago

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Apr 30, 2024, 12:06 AM EDT - 2 years ago

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11, 2024, 9:00 AM EDT - 2 years ago

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

VKTX, JANX and these biotech stocks are surging in 2024

Apr 2, 2024, 2:10 AM EDT - 2 years ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT VKTX AMLX MCRB RAPT RVNC

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Mar 20, 2024, 1:44 PM EDT - 2 years ago

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 8, 2024, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Feb 29, 2024, 1:22 AM EST - 2 years ago

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27, 2024, 5:15 PM EST - 2 years ago

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Feb 27, 2024, 5:00 PM EST - 2 years ago

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Feb 27, 2024, 8:38 AM EST - 2 years ago

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

MarketWarfare
MarketWarfare Mar. 17 at 7:30 PM
$JANX broken, pathetic stock. Wasting all these green days so that when the market turns red, we'll get an easy 5% decline. CEO needs to go.
0 · Reply
Dieselprints
Dieselprints Mar. 16 at 5:06 PM
$JANX picked up 1k shares
0 · Reply
bizness1957
bizness1957 Mar. 16 at 1:55 PM
$JANX should break out today
0 · Reply
bc4
bc4 Mar. 13 at 4:12 PM
$JANX This seems to be algo trading on this stock. The patern and timing of short and cover always the same everyday.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 12 at 10:42 PM
$JANX RSI: 64.84, MACD: 0.0308 Vol: 0.37, MA20: 13.62, MA50: 13.71 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
nikserr
nikserr Mar. 12 at 5:45 PM
$JANX Started accumulating … Easy 20+
0 · Reply
MarketWarfare
MarketWarfare Mar. 12 at 1:57 PM
$JANX market down 600, janx down 50 cents. Market up 600, janx up 1 cent. Nothing changes until the pos CEO is removed. He's abysmal.
0 · Reply
aletz
aletz Mar. 12 at 1:47 PM
$JANX https://www.biostockinfo.com/t-cell-engagers-tce-the-race-to-reset-the-immune-system-and-the-biotechs-positioning-to-win/ This can help understand what TCE is about and how JANX-011 fits in the space
0 · Reply
Suhair1977
Suhair1977 Mar. 12 at 9:50 AM
$JANX Price targets $80 and $100. Let’s talk about $20 first
0 · Reply
MarketWarfare
MarketWarfare Mar. 10 at 4:12 PM
$JANX green market, dead stock. What else is new?
0 · Reply
bizness1957
bizness1957 Mar. 9 at 7:09 PM
$JANX appears to be under accumulation
0 · Reply
ilestz
ilestz Mar. 6 at 3:28 PM
$JANX theres literally no reason why this should go back down so naturally it will because the shorts need to be in control
2 · Reply
DanteLowell
DanteLowell Mar. 5 at 5:38 PM
$JANX biotech tightening range if volume expands breakout risk increases
1 · Reply
bizness1957
bizness1957 Mar. 5 at 3:38 PM
$JANX still trading $100 milll under cash
0 · Reply
Lagoule
Lagoule Mar. 4 at 7:42 PM
$JANX Biotech, severely injured, with 100% …200%+ potential ‼️😝 Analyst Sentiment: the consensus among 10 analysts remains a "Buy" with an average 1-year price target of $53.60.
0 · Reply
Jstu10
Jstu10 Mar. 4 at 6:56 PM
$JANX Just the beginning after months of being beat down.
0 · Reply
bc4
bc4 Mar. 4 at 6:39 PM
$JANX I don't need 100. Anything above 20 is good for me
1 · Reply
Letsdothis1001
Letsdothis1001 Mar. 4 at 6:36 PM
$JANX
0 · Reply
GSTX7
GSTX7 Mar. 4 at 6:00 PM
$JANX Here we go! $100 and $80 PT this week. I know only 500% upside but beggars can't be choosers lol.
0 · Reply
Lagoule
Lagoule Mar. 4 at 5:05 PM
$JANX short interest!
0 · Reply
bizness1957
bizness1957 Mar. 4 at 4:59 PM
$JANX breakout
0 · Reply
Lagoule
Lagoule Mar. 4 at 4:57 PM
$JANX PT…$100‼️😱🤩👍 https://www.marketbeat.com/instant-alerts/cantor-fitzgerald-has-lowered-expectations-for-janux-therapeutics-nasdaqjanx-stock-price-2026-02-27/
0 · Reply